Pieris Pharmaceuticals Net Income vs. Price To Book
| PIRS Stock | USD 16.25 0.58 3.45% |
Net Loss | First Reported 2013-09-30 | Previous Quarter -3.6 M | Current Value -2.9 M | Quarterly Volatility 5.1 M |
For Pieris Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pieris Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pieris Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pieris Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pieris Pharmaceuticals over time as well as its relative position and ranking within its peers.
Pieris |
Pieris Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pieris Pharmaceuticals. If investors know Pieris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pieris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.11) | Revenue Per Share 16.66 | Quarterly Revenue Growth (0.97) | Return On Assets (0.13) | Return On Equity (0.80) |
The market value of Pieris Pharmaceuticals is measured differently than its book value, which is the value of Pieris that is recorded on the company's balance sheet. Investors also form their own opinion of Pieris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pieris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pieris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pieris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pieris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pieris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pieris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Pieris Pharmaceuticals Price To Book vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Pieris Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Pieris Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Pieris Pharmaceuticals is regarded second in net income category among its peers. It is rated below average in price to book category among its peers . At this time, Pieris Pharmaceuticals' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pieris Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Pieris Price To Book vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Pieris Pharmaceuticals |
| = | (24.54 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Pieris Pharmaceuticals |
| = | 1.37 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Pieris Price To Book Comparison
Pieris Pharmaceuticals is currently under evaluation in price to book category among its peers.
Pieris Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Pieris Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pieris Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Pieris Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Pieris Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 28 K | 29.4 K | |
| Operating Income | -29.8 M | -31.2 M | |
| Income Before Tax | -24.5 M | -25.8 M | |
| Total Other Income Expense Net | 5.2 M | 5.5 M | |
| Net Loss | -24.5 M | -25.8 M | |
| Income Tax Expense | 13.9 M | 14.6 M | |
| Net Loss | -28.1 M | -29.5 M | |
| Net Loss | -41.2 M | -39.1 M | |
| Non Operating Income Net Other | 2.8 M | 2.9 M | |
| Interest Income | 1.7 M | 1.8 M | |
| Net Interest Income | 1.7 M | 936.8 K | |
| Change To Netincome | 6 M | 4 M | |
| Net Loss | (21.80) | (22.89) | |
| Income Quality | 2.19 | 2.30 | |
| Net Income Per E B T | 1.08 | 1.09 |
Pieris Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Pieris Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pieris Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pieris Pharmaceuticals' important profitability drivers and their relationship over time.
Use Pieris Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pieris Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pieris Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Pieris Pharmaceuticals Pair Trading
Pieris Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Pieris Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pieris Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pieris Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pieris Pharmaceuticals to buy it.
The correlation of Pieris Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pieris Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pieris Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pieris Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Pieris Pharmaceuticals position
In addition to having Pieris Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Monster Funds Thematic Idea Now
Monster Funds
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.